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Background:OxLDL and the high level of hyaluronan are major triggering factors of atherosclerosis.
Results: The oxLDL load of the aortic human smooth muscle cells (SMC) via the scavenger receptor LOX-1 causes ER stress,
overexpression of HAS2, and hyaluronan deposition.
Conclusion: the oxidized sterols driven into the SMC by oxLDL have a role in hyaluronan metabolism.
Significance: oxLDL influences extracellular matrix hyaluronan.
Thickening of the vessel in response to high low density lipo-
protein(s) (LDL) levels is a hallmark of atherosclerosis, charac-
terized by increased hyaluronan (HA) deposition in the
neointima. Human native LDL trapped within the arterial wall
undergoes modifications such as oxidation (oxLDL). The aim of
our study is to elucidate the link between internalization of
oxLDL and HA production in vitro, using human aortic smooth
muscle cells. LDL were used at an effective protein concentra-
tion of 20–50 g/ml, which allowed 80% cell viability. HA con-
tent in the medium of untreated cells was 28.9 3.7 nmol HA-
disaccharide/cell and increased after oxLDL treatment to 53.9
5.6. OxLDL treatments doubled the transcripts of HA synthase
HAS2 andHAS3. AccumulatedHA stimulatedmigration of aor-
tic smooth muscle cells andmonocyte adhesiveness to extracel-
lular matrix. The effects induced by oxLDL were inhibited by
blocking LOX-1 scavenger receptor with a specific antibody (10
g/ml). The cholesterol moiety of LDL has an important role in
HA accumulation because cholesterol-free oxLDL failed to induce
HA synthesis. Nevertheless, cholesterol-free oxLDL and unmodi-
fied cholesterol (20 g/ml) induce only HAS3 transcription,
whereas 22,oxysterol affects bothHAS2 andHAS3. Moreover, HA
deposition was associated with higher expression of endoplasmic
reticulum stress markers (CHOP and GRP78). Our data suggest
that HA synthesis can be induced in response to specific oxidized
sterol-related species delivered through oxLDL.
Atherosclerosis, usually classified as a chronic inflammatory
disease of the blood vessel wall, is the most common cause of
cardiovascular diseases. The localized inflammation causes the
thickening of the arterial wall due to the increased deposition of
extracellular matrix (ECM).3 The newly formed ECM traps
lipoprotein and inflammatory/growth factors from the circula-
tion within the vessel wall (1). The atheromatous plaque is
therefore formed by a central core of cholesterol crystals and
foam cells encircled by altered ECM.
Despite the many cardiovascular risk factors reported in
published guidelines and reduction strategies, recent studies
underscored again the relevance of plasma lipoproteins (LDL)
in the pathogenesis of atherosclerosis (2). In particular, the ratio
of the protein moieties of the lipoproteins ApoB/ApoA1
(reflecting LDL/HDL amounts) and the quantification of the
circulating LDL-cholesterol are at the moment the routine risk
factors evaluated in the daily clinical practice. The chronic and
repeated exposure to pathogenic risk factors triggers a complex
interplay between circulating species, such as monocytes and
lymphocytes, and various cell types, resident within the arterial
wall, including endothelial cells and smooth muscle cells
(SMC).
In the healthy arterial vessel wall, endothelial cells regulate
the vascular tone, the thrombosis/fibrinolysis balance, and the
recruitment of inflammatory cells; most of these abilities are
due to ECM that is enriched with hyaluronan (HA), which
forms the glycocalyx. Although the HA within the arterial wall
is present in physiological conditions predominantly in the
tunica adventitia produced by vascular SMC, during the ath-
erosclerotic process HA, is highly synthesized and also depos-
ited in the neointima (3–5), thus contributing to the thickening
of the arterial wall.
HA is a nonsulfated glycosaminoglycan that is present in
ECMs as a polyanionic chain of up to 107 Da. Several cell types,
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scavenger receptor for phosphatidylserine andoxidized lipoprotein; SR-AI,
scavenger receptor AI; CD36, class B scavenger receptor; CD, (2-hydroxy-
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protein; C/EBP, CCAAT-enhancer-binding protein; GRP78, glucose-regu-
lated protein 78; SREBP, sterol regulatory element binding protein;
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including aortic SMC (AoSMC), produce HA either in physio-
logical or in pathological conditions. HA is the only glycosami-
noglycan synthesized at the plasma membrane (6) from cyto-
plasmic UDP-sugar precursors. TheHA synthases (HASs) are a
family of three members (HAS1, HAS2, and HAS3), each one
characterized by expression timelines and regulation at tran-
scriptional and/or post-transcriptional levels (7, 8). HA, both
secreted and pericellular, is known to have a pivotal role in cell
migration, proliferation, and leukocyte adhesion in the athero-
sclerotic plaques (9, 10). Inflammation processes are strongly
influenced by HA (11). Merrilees et al. (12) demonstrated in an
in vivo model that monocytes localize in the atherosclerotic
plaque in anHA-dependentmanner and that theHA-rich ECM
is promoted by the presence of oxidized LDL (oxLDL). Given
the numerous oxidative events associated with the develop-
ment of an inflammatory atherosclerotic plaque (13), LDL,
which accumulate early in the intima primarily from enhanced
retention by the glycosaminoglycans (1, 12, 14), are converted
into aggregated LDL (aggLDL) (15) and/or oxLDL (16).OxLDL,
in addition to the proper oxidized lipid products, also contains
lysophospholipids, hydrolytic derivatives of oxidized phospho-
lipids, prostanoids, isoprostanoids, leukotrienes, which are
derived from the oxidation of arachidonic acid (17), and oxy-
sterols (18), which contribute to reactive oxygen species gener-
ation and amplification of the steps described thus far (19).
Although the majority of SMC in the arterial wall are con-
tainedwithin themedial layer, a significant number exist within
the intima as well. Those SMC retain a certain degree of plas-
ticity, altering their expression of cell-specific genes in response
to many stimuli, i.e. switching from the “contractile” to the
“synthetic” phenotypic state. This phenotypic switch can be
triggered by several atherogenic stimuli, such as ECM compo-
sition, cytokines, shear stress, reactive oxygen species, and lip-
ids, and is associated with different behaviors of SMC (20).
Moreover, those SMC can also give rise to a significant number
of lipid-laden cells, although the larger portion of the foam cells
derives from macrophages (20, 21). The lipid load can induce
endoplasmic reticulum (ER) stress (22, 23) that is associated
with oxidative stress (24) and can enhance atherosclerosis
progression.
In this study, we used a cellular model to investigate the cor-
relation between the exposure of AoSMC to oxLDL and the
accumulation of HA. In particular, we analyzed at the molecu-
lar level the mechanisms that induced AoSMC to produce an
HA-enriched ECM, the role of the oxLDL in delivering mole-
cules that can trigger the phenotypic switch, and the eventual
contribution of cholesterol to this early atherogenic event.
EXPERIMENTAL PROCEDURES
Cell Culture—Human AoSMC were purchased from Lonza
and grown in the complete SmGm2 culture medium (Lonza,
Basel, Switzerland) supplemented with 5% FBS as described
previously (25). 1.5 105 cells were seeded in a 6-well plate at
70–80% confluence. They were incubated for 48 h in DMEM
with 0.2% FBS medium and afterward supplemented with
SmGm2, 5% FBS and incubated for a further 48 h with different
concentrations of native, oxidized, and aggregated LDL (nLDL,
oxLDL, and aggLDL, respectively). Cell viability was evaluated
with trypan blue staining. Monocyte U937 cells were grown in
suspension culture in RPMI 1640 medium containing 10% FBS
and routinely cultured at 1–10 105 cells/ml.
LDL Isolation—Native LDL (nLDL, d  1.019–1.063 g/ml)
were purified fromplasmaof normocholesterolemic volunteers
kindly provided by the “Ospedale di Circolo” following the
method described in Ref. 26. OxLDL were obtained by incuba-
tion of 100g/ml nLDLwith 5MCuSO4 at 37 °C for 16–18 h,
and the reaction was then stopped with EDTA 1 mM. The
oxLDL were desalted by filtration in PD-10 columns (GE
Healthcare) and concentrated with Centriprep concentrators
(10 kDa NMWL, nominal molecular weight limit) (Amicon).
AggLDLs were obtained by vortexing nLDL for 5 min at room
temperature (15). The nLDLswere treated overnightwith 5mM
methyl--cyclodextrin (Sigma) (27) at 37 °C with gentle mix-
ing, and excess of methyl--cyclodextrin was eliminated by fil-
tration onPD-10 columns to obtain the cholesterol-free formof
LDL (CF-nLDL). CF-nLDLs were then subjected to oxidation
as described above, and oxidized cholesterol-free LDLs (CF-
oxLDLs) were obtained. All LDL preparations were sterilized
by filtration through 0.2-m filters. Protein contents were
determined by the Bradford assay, and total cholesterol was
quantified by a colorimetric enzymatic assay (Olympus Choles-
terol OSR6516). The purity of LDL preparations was assessed
by agarose gel electrophoresis. Briefly, 50 g of total proteins
were added with the same volume of Sudan black (Sigma) 2
mg/ml in ethanol, 2% glycerol, incubated at room temperature
in the dark for 1 h, loaded in a 0.5% agarose gel inTAEbuffer (40
mM Tris, 20 mM acetic acid, 1 mM EDTA), and run with 0.05 M
thiobarbituric acid buffer pH 8.5, 100 V for 30 min. Anti-scav-
enger receptor LOX-1 antibody was added at a final concentra-
tion of 10 g/ml.
Cholesterol Loading—Cholesterol was delivered to AoSMC
in a complex with (2-hydroxypropyl)--cyclodextrin solution
(CD) (Sigma), a cyclic oligosaccharide that solubilizes choles-
terol and can be used as a “carrier” molecule. The mixture was
prepared as described previously (27)with a final concentration
of 10 g/ml cholesterol. When CD-cholesterol complex was
added to cell culture, the final CD concentration was 2.5 mM,
which was therefore added to AoSMC as a further control.
LXRAssays—(22)(R)-Hydrocholesterol (Sigma)was added to
the culture medium at a final concentration of 7.5 M for 48 h.
DiI Labeling—nLDL and oxLDL were labeled with DiI (1,1-
dioctadecyl-3,3,3,3-tetramethylindocarbocyanine perchlo-
rate, Molecular Probes) following the procedure described pre-
viously (28). Briefly, LDL preparations at 1 mg/ml were
incubatedwithDiI 3mg/ml inDMSOovernight at 37 °C, recov-
ered by ultracentrifugation, and concentrated. Images of
AoSMC after a 24-h treatment with 20 g/ml nLDL-DiI or
oxLDL-DiI, in the absence or presence of anti-LOX-1 antibody
(10 g/ml), were captured using fluorescence microscopy
(Olympus), and the cell fluorescence was quantified using the
ImageJ software (58) and expressed as corrected total cell
fluorescence.
Gene Expression—Total RNA was extracted from AoSMC
cultures with TRIzol (Invitrogen, Milan, Italy), digested with
Turbo DNase (Ambion, Monza, Italy), retrotranscribed by the
High Capacity cDNA synthesis kit (Applied Biosystems, Monza,
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Italy), and amplified on an ABI Prism 7000 instrument (Applied
Biosystems) using the TaqMan universal PCR master mix
(Applied Biosystems) following the manufacturer’s instruc-
tions. The following human TaqMan gene expression assays
were used: HAS1 (Hs00155410), HAS2 (Hs00193435_
m1), HAS3 (Hs00193436_m1), CHOP (Hs01090850_m1),
GRP78 (Hs00946084_g1), and the housekeeping gene -actin
(Hs99999903_m1). The relative quantification of gene expression
was determined by comparing 2Ct (29). For semiquantitative
RT-PCRanalysesofLDLscavenger receptors, cDNAswereampli-
fied using the following primers: LOX-1 (forward, 5-GCCATTC-
CGAAATCAAGAAA-3 and reverse, 5-AGGAGTCATCAGG-
AGGAGCA-3, SR-PSOX (forward, 5-TACACGAGGTTCCA-
GCTCCT-3 and reverse, 5-TACCATGTTGTCAGGGGTCA-
3), SR-AI (forward, 5-GGAACACATGAGCAACATGG-3 and
reverse, 5-CCAAGCTCCTACAGACGACC-3), CD36 (for-
ward, 5-GGCTGAGCAAGGTTGACTTC-3 and reverse, 5-
CCTCCTTATCCTTTGAGCCC-3), LRP1 (forward, 5-ACCA-
CCAGCTACCTCATTGG-3 and reverse, 5-TTGTTCTCGCA-
CTTGAATCG-3),andhousekeeping-actin(forward,5-CTCTT-
CCAGCCTTCCTTCCT-3 and reverse, 5-ATGCTATCACCT-
CCCCTGTG-3). Amplifications of cDNA were done using the
first strand cDNA synthesis mixture, 0.1 M forward and reverse
primers, 200 M dNTPs, and RedTaq polymerase (Sigma) in its
ownbuffer.Reactionmixtureswere subjected to35cycleswith the
following parameters: denaturation at 94 °C for 30 s, annealing at
52 °C for 40 s, and elongation at 72 °C for 1min.
HADetermination—HAreleased into themediumwas quan-
tified by HPLC analysis as described previously (30). HA in the
pericellular coating was determined as in Ref. 25, quantified
after particle exclusion assay using ImageJ software, and
expressed as the percentage of total area (pericellular coating
area/(cell area pericellular coating area)100).
Cell Mobility Assay—Migration assay was done as described
previously in Ref. 25 with quantification by Image J software as
follows. Wound area was measured at time 0 (t0) and after 24 h
(t24), and the wound closure was determined by the equation:
((wound area t0  wound area t24)/wound area t0)100.
AoSMC cultures were treated with 4-methylumbelliferone in
DMSO at a final concentration of 1 mM (25).
Monocyte Adhesion Assay—Adhesion assay was performed
using the monocyte U937 cell line as described previously in
Ref. 31. Briefly, U937 were labeled with fluorescent green Cyto-
Tracker (Invitrogen, Milan, Italy) vital stain and plated on
AoSMC incubated with oxLDL. As control, AoSMC were pre-
treated with 2 units/l Streptomyces hyaluronidase (Seikagaku
Corp., Tokyo, Japan). After PBS washing, the adherent cells
were quantified under a fluorescent microscope (Olympus,
Segrate, Italy).
Statistical Analysis—GraphPad Prism version 5.01 for Win-
dows and GraphPad Software were used for statistical analysis.
The number of independent replicate experiments is indicated
in each figure legend. Data are presented as means of indepen-
dent experiments S.E. Statistical significance was tested with
analysis of variance followed by Bonferroni’s post hoc test, or in
Fig. 5B, by unpaired Student’s t test. Statistically significant val-
ues of p are reported in the figure legends.
RESULTS
Oxidized LDL IncreaseHA Secretion inAoSMCby Enhancing
HAS2 and HAS3 mRNA Levels—To investigate how LDL par-
ticles may affect glycosaminoglycans secreted by AoSMC and
contribute to the onset of atherosclerosis, we subjectedAoSMC
to 48 h of treatment with different LDLs. Increasing amounts of
nLDL, oxLDL, and aggLDL were added to cultured cells, and
the cell viability was evaluated after 48 h (Fig. 1A). Nontoxic
concentrations spanned the range of 10–50 g of LDL pro-
teins/ml for all the preparations, with an average of more than
80% of total vital cells after the exposure. At higher concentra-
tions, oxLDL and aggLDLwere toxic to AoSMC, with the high-
est effect obtained with oxLDL. Treatment with 20–50 g/ml
of either nLDL or aggLDL did notmodify HA secretion into the
culture medium beyond control level (Fig. 1B). In contrast,
oxLDLs at these concentrations significantly increased HA
secretion, from 28.9  3.7 nmol -HA/cell of the control to
53.9 5.6 and 61.0 2.8 nmol -HA/cell in 20 and 50 g/ml
oxLDL treatments, respectively (Fig. 1B). Interestingly, the
20–50 g/ml concentrations of oxLDL were able to produce a
similar effect on HA secretion. Because aggLDL did not influ-
ence the levels of either HA or CS (data not shown), they were
not tested further. AoSMC pericellular coat was also increased
after 48 h of treatment with oxLDL as compared with control
and nLDL-treated cultures (Fig. 1C). The increase was mainly
constituted by HA because hyaluronidase digestion restored
the sizes to control levels as shown by quantification after par-
ticle exclusion assays (Fig. 1C). Again, the coating sizes at the
two concentrations of oxLDL were nearly the same. Therefore,
in the following experiments, only the lowest active amount (20
g/ml) was used. Because AoSMC can express three hyaluro-
nan synthases (32), we measured the levels of their mRNAs.
HAS1mRNAwas not significantly detected inAoSMCcultures
(data not shown). The expression ofHAS2 in untreatedAoSMC
was about 30-fold higher as compared withHAS3 (Fig. 1D, low-
est panel). HAS2 and HAS3 mRNA levels were both doubled
after 48 h of oxLDL exposure (Fig. 1D, upper panels) as com-
pared with control and nLDL treatments. The enhanced HA
synthesis could therefore be due to the increases of the hyalu-
ronan synthases 2 and 3 transcripts.
Increased HA Affects in Vitro Motility and AoSMC ECM
Adhesiveness—Cellmigration, a critical event in atherosclerosis
development, can be regulated by HA (25).We therefore tested
whether oxLDL can affect cell motility by scratch assays. Expo-
sure to oxLDL increased the migration ability41 and 33% as
comparedwith control and nLDL treatments, respectively. The
increased migration depends on HA because treatment with
4-methylumbelliferone, an inhibitor of HA synthesis (25),
restored initial migration levels (Fig. 2A). In addition, HA pro-
duced by oxLDL treatment enhanced adhesion of U937 mono-
cytic cells (Fig. 2B). Digestion with hyaluronidase significantly
decreased the monocyte adhesion, but did not completely
revert the adhesion to control level, probably due to the
unmasking of other adhesion molecules (i.e. integrins).
LOX-1 Scavenger Receptor Mediates oxLDL Internalization
and HA Secretion—A number of scavenger receptors involved
in cholesterolmetabolism are known to bindmodified LDL and
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to be expressed by human AoSMC (20, 33). SR-PSOX and
LOX-1 specifically recognize oxLDL, and SR-AI andCD36 bind
oxLDL and also acetylated LDL. In addition, LDL receptor-
related protein 1 (LRP1) is known to have a specific role in
uptake of aggLDL (15). We therefore screened by PCR the
expression of various scavenger receptors in our cellmodel (Fig.
3A) and found that CD36 and LRP1 were already present on
untreated cells. LOX-1 and SR-PSOX, the specific oxLDL
receptors, together with SR-AI, were very poorly expressed by
resting AoSMC (the primers were tested usingU937 cells RNA,
data not shown). Nevertheless, expression of scavenger recep-
tors may be induced by exposure to modified LDLs. Indeed,
after oxLDL exposure, LOX-1 was the only receptor to be up-
regulated, in good agreement with data from literature (34),
whereas no up-regulation was detected following nLDL expo-
sure. The expression of SR-PSOX, SR-AI, CD36, and LRP1 was
not increased upon oxLDL exposure.
LOX-1 receptor is recognized as themajor player in internal-
ization of oxLDL in a variety of cells (35, 36), and it is known to
be up-regulated in response to oxLDL exposure. Thus, we
investigated the involvement of LOX-1 in oxLDL uptake and
HA secretion in AoSMC by blocking with a specific antibody
that was added to cell cultures at time 0 and re-added at the
same concentration after 24 h to overcome any degradation of
the antibody. To evaluate uptake, AoSMC were treated with
DiI-labeled nLDL or oxLDL, and the DiI fluorescence was
quantified after 24 h (Fig. 3B). Both nLDL-DiI and oxLDL-DiI
were taken up as assessed by fluorescence intensity measured
within the cells. Labeled oxLDL-DiI was internalized with a
higher rate as compared with nLDL-DiI although the incre-
FIGURE 1. Effect of different LDL particles on AoSMC viability, HA, secretion, and HAS expression. A, viability of AoSMC after 48 h of treatment with
increasing amounts of nLDL (empty circles), oxLDL (empty squares), and aggLDL (filled triangles) was evaluated by trypan blue staining and expressed as the
percentage of the total cell number. B, AoSMCwere treatedwith different amounts (20 and 50g of LDL proteins/ml) of nLDL (striped bars), oxLDL (filled bars),
or aggLDL (dotted bars) for 48 h in complete medium. Media were collected, and glycosaminoglycans were precipitated and quantified by HPLC. Amounts of
-HA disaccharides from hyaluronidase digests of HA secreted into the media after the treatments are shown with respect to control (white bar). Values are
meanS.E. of triplicates, **,p	0.01, ***,p	0.001.C, quantificationofHApericellular coatingafter 24hof treatmentwithnLDLandoxLDL. Values aremean
S.E. of triplicates, ***, p	 0.01, ***, p	 0.001.D, quantitative RT-PCR analysis of HAS expression in AoSMC treatedwith or without (CNT) 20g of nLDL (striped
bars) or oxLDL (filledbars). RNA fromAoSMCwasanalyzed forHAS2 (emptybars) andHAS3 (filledbars) expressionusing-actin ashousekeepinggene. The result
is expressed as relative expression of the HAS3 and HAS2 genes in the treatments with respect to the untreated AoSMC (CNT). The lower panel represents the
relative expression ofHAS3with respect to HAS2 and for each gene, with respect to CNT. Data aremean S.E. of three independent experiments **, p	 0.01,
***, p	 0.001.
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ment in total fluorescence was not statistically different. It is
noteworthy that the simultaneous presence of anti-LOX-1
antibody significantly affected the total fluorescence of
oxLDL-DiI-treated AoSMC but had no effect on nLDL-DiI-
treated cells.
In addition, when cells were exposed to oxLDL in the pres-
ence of anti-LOX-1 antibody, the amount of HA within the
culture medium was strongly reduced to concentrations found
in untreated cells (Fig. 3C). HA release by untreated and nLDL-
treated cells was not affected by the presence of LOX-1 anti-
body. Scavenger receptor LOX-1 appears to be the preferential
way bywhich oxLDL enter the cells and influenceHA secretion.
Moreover, in the context of oxLDL exposure, treatment with
anti-LOX-1 antibody reduced the expression ofHAS2 and,with
a lesser extent, of HAS3 (Fig. 3D). Treatment with a control
antibody (anti--tubulin) had no significant effect on either
HAS2 or HAS3mRNA levels (data not shown).
HAS Expression Depends on Oxidized Sterol-related Species
in oxLDL—To assess whether the excess of cholesterol deliv-
ered through oxLDLwas responsible for the increased HA syn-
thesis, we prepared cholesterol-depleted oxLDL by treatment
with methyl--cyclodextrin, which specifically removes cho-
lesterol from membranes and lipoproteins (27). The particles
obtained, CF-nLDL, were then oxidized and namedCF-oxLDL.
Theywere then stainedwith Sudan black and run on an agarose
gel to check their mobility (Fig. 4A, inset). Indeed, CF-nLDL
and CF-oxLDL showed higher electrophoretic mobilities as
compared with nLDL and oxLDL. Total cholesterol content
diminished as was confirmed by quantification. The ratio of
cholesterol/proteins, which spanned the range 0.9–1.6 in all
nLDL and oxLDLpreparations used, was decreased to 0.1–0.47
in CF-nLDL and CF-oxLDL. Neither CF-oxLDL nor CF-nLDL
stimulated HA release in the medium (Fig. 4A) as compared
with levels of untreated AoSMC (CNT).
Quantitative RT-PCR analysis of HAS expression showed
that HAS2 was not increased by exposure to CF-oxLDL (Fig.
4B) with respect to its control. On the other hand, HAS3
expression appeared not to be modulated in the same fashion
because a higher level of mRNA was measured in CF-oxLDL-
andCF-nLDL-treatedAoSMC.The different response ofHAS3
transcription with respect to HAS2 not related to the HA pro-
duction suggests a possible alternative role of the enzyme in
cells behavior, e.g. adhesion or motility mechanisms.
OxLDL Treatment Induces Endoplasmic Reticulum Stress in
AoSMC—Because lipid load and excess of cholesterol might
lead to ER stress (22), we determined whether oxLDL expo-
sure maymodulate levels ofCHOP andGRP78, marker genes
for the ER membrane stress in AoSMC. Because ER stress is
FIGURE 2. OxLDL modulates migration and ECM adhesive properties of
AoSMC. A, evaluation of AoSMC migration ability by scratch assay. AoSMC
were serum-deprived (0.2%FBS) for 48h and scratchedwith apipette tip, and
new complete medium was added with or without (CNT) 20 g of nLDL,
oxLDL, or oxLDL  1 mM 4-methylumbelliferone (4-MU). The migration was
followed up to 24 h, and themobility ratewas calculatedwith respect to time
0 for each treatment as the percentage of the repopulated area with respect
to the starting scratched area, using the ImageJ software. Results are
expressed as mean S.E. of three independent experiments, ** p	 0.01. B,
U937monocyte adhesion assays were done on AoSMC alone or treated with
20 g of oxLDL. After 48 h, fluorescent U937 cells were added for 20 min at
37 °C, washed, and counted under a fluorescence microscope. As control,
cells were treated with hyaluronidase. The experiments were repeated three
times. Results are expressed as number of adherent U937 cells per field and
are shown as mean S.E., ***, p	 0.001.
FIGURE 3. LOX-1 scavenger receptor is responsible for the internalization
of oxLDL andmediates their effect. A, RT-PCR analysis of scavenger recep-
tors LOX-1, SR-PSOX, SR-AI, CD36, and LRP1 and of housekeeping gene -ac-
tin in untreated AoSMC and after exposure to 20 g of nLDL or oxLDL. B,
quantification of corrected total cell fluorescence (CTCF) in AoSMC treated
with 20 g of nLDL-DiI and oxLDL-DiI in the absence () or presence () of
anti-LOX-1 antibody. Results are expressed as corrected total cell fluores-
cence and represented as mean S.E., *, p	 0.05. C, quantification by HPLC
analysis of HA disaccharides of hyaluronidase digests of HA secreted in
culture medium of AoSMC untreated (CNT) or treated with 20 g of nLDL
or oxLDL. Cells were subjected () or not () to the simultaneous treat-
ment with anti-LOX-1 antibody. D, quantitative RT-PCR analysis of HAS2
and HAS3 expression of CNT- and oxLDL-treated AoSMC from C. Results
are expressed as relative expression of the HAS3 and HAS2 genes in the
treatments with respect to the untreated AoSMC (CNT) ( anti-LOX-1).
Values are mean S.E. of triplicates of two independent experiments, **,
p 	 0.01, ***, p 	 0.001.
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a fast event, the transcript levelswere checked after 24 h of expo-
sure.OxLDL induced an up-regulation of bothCHOP andGRP78
24 h after the treatment, whereas nLDL showed no effect. Inter-
estingly, the induction of ER stress was abolished when cells were
simultaneously exposed to LOX-1 antibody (Fig. 5,A and B).
TheHAS2 andHAS3 induction seems therefore related to an
oxidized sterol-related specie driven inside the cells without
regulation by the oxLDL. To assess this hypothesis, we used
both unmodified cholesterol and the sterol 22(R)-hydrocholes-
terol, targeting the LXR/RXR sterol sensor system, to investi-
gate their involvement in the expression of the enzymes. In fact,
liver X receptors (LXR) of the nuclear receptor superfamily are
factors that regulate the transcription of several genes involved
in cholesterol metabolism.
AoSMC were exposed to CD-cholesterol, a complex used as
a sterol donor to induce cholesterol loading of cell membranes
(37, 38), using as control CD-treated AoSMC (Fig. 5C) (CNT
CD), with the evidence that cholesterol alone increased only the
HAS3 expression 3.2-fold. A similar situation, with an even
more significant effect on both HAS2 and HAS3 gene expres-
sion, was evidenced using the (22)R-hydrocholesterol, herein-
after named 22,oxysterol (39, 40) (Fig. 5C) in which we had an
increase of 8.8- and 9.3-fold, respectively.
DISCUSSION
The results of our work demonstrate that internalization of
oxLDL by AoSMC via scavenger receptor LOX-1 increases the
synthesis and secretion of HA through regulation of the HAS2
gene, and possibly the HAS3 gene, at the transcriptional level
and that this effect is due to oxidized sterol overload of the cell.
LDL retention at the subendothelial level is one of the first
events triggering atherosclerosis, with the concurrent involve-
ment of SMC for the disease onset and progression (20, 41). It
has been shown that, together with macrophages, AoSMC
overloaded with cholesterol contribute to foam cell formation
(21), highlighting the emerging role of this cell type in early
atherosclerosis. AoSMC are known to highly synthesize HA,
which is one of the major components of ECM that regulates a
variety of processes (e.g. proliferation, adhesion, andmigration)
in physiological conditions. It is also known to be accumulated
in ECMs in vivo both in human (9, 42) and in animal models of
atherosclerosis (5). Thus, AoSMC are a good model to explore
the link between HA deposition in atherosclerotic plaque and
the LDL/cholesterol altered metabolism as well as macro-
phages (43). LDL chemical modifications (aggregation and oxi-
dation) are processes occurring in vivo as a consequence of LDL
trapping within the arterial wall. Oxidation is the most repre-
sentative modification, and several enzymatic and nonenzy-
matic oxidant candidates have been described to be involved
(16).Oxidationmay affect both lipid and proteinmoieties of the
particles, and as a result, a series of biologically active species
including peroxides, aldehydes, and oxysterols may be pro-
duced (44, 45). Intracellular and cell membrane cholesterol
contents are finely regulated by a feedback system (46) involv-
ing: regulated nLDL uptake by LDL receptor; a fine balance
between biosynthesis and efflux (47); cholesterol acylation/
deacylation; and cholesterol intracellular trafficking between
organellemembranes (mainly ER, lysosomes, and plasmamem-
brane) (48, 49). Nevertheless, modified LDL can escape the reg-
ulated uptake and enter the cell via a series of unregulated scav-
enger receptors (20, 33). In particular, scavenger receptor
LOX-1 expression was reported to be altered in atherosclerotic
lesions (34, 35). Here we show that LOX-1 is a preferential
receptor through which oxLDL is internalized by AoSMC.
Incorporated oxLDL significantly decreased when the receptor
was blocked by a specific antibody. Other scavenger receptors
may contribute to the uptake because fluorescence associated
with oxLDL is not completely erased by blocking of LOX-1.
OxLDL internalization in the absence of antibody was not sig-
nificantly increased with respect to nLDL uptake most likely
FIGURE 4. HAS expression depends on oxidized sterol-related species in
oxLDL. A, quantification by HPLC analysis of-HA disaccharides of hyaluron-
idase digests of HA secreted in culture medium of controls (CNT) and treated
AoSMC as indicated (20 g of proteins each). Values are mean S.E. of trip-
licates of three independent experiments, ***, p  0.001. Electrophoretic
mobility of nLDL, oxLDL, and cholesterol-free LDL forms on agarose gel are
shown in the inset, and the direction of migration is indicated by an arrow. B,
quantitative RT-PCR analysis of HAS2 and HAS3 expression of samples
depicted in A. Results are expressed as relative expression of HAS3 and HAS2
for eachgenewith respect to its control (CNT). Values aremean S.E. of three
independent experiments, *, p	 0.05, **, p	 0.01.
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because a longer time is necessary for oxLDL to induce overex-
pression of the LOX-1 receptor. Entrance of nLDL instead was
independent of LOX-1.
HA accumulation in both culture medium and pericellular
coating followed the stimulation with oxLDL. The HA-en-
riched ECM of the AoSMC is responsible for their altered
migratory ability and the increased monocyte adhesion.
Although both HAS2 and HAS3 transcripts were found
increased concomitantly with oxLDL treatment, HAS2 and
HAS3 expression is not followed by HA production due to the
same mechanism.
In fact, HA was reduced to CNT level when oxLDL capture
was blocked by anti-LOX-1 antibody concomitantly withHAS2
and HAS3 transcript reduction, but after exposure to CF-ox-
LDL, HA decreased to CNT level due to HAS2 but not HAS3
down-regulation. Moreover, HAS3 transcripts were signifi-
cantly higher with respect to CNT following both oxLDL (1.6-
fold) (blocked by the anti-LOX-1 antibody, Fig. 3D) and CF-
oxLDL (1.9-fold) exposure, although the latterwas not reflected
in an increment in HA levels. The possible explanation of this
finding is thatHAS2 is themain hyaluronan synthase expressed
by AoSMC. In the same cell model, our group previously dem-
onstrated by siRNA that HAS2 accounted for 70% of total HA
secretion versus 30% by HAS3 (25). HAS3 contribution to total
HA content is therefore secondary. Moreover, several studies
onAoSMCpointed out the pivotal role inHAproduction of the
post-transduction regulation of the enzymes (7, 50, 51).
HAS2 in vitro induction is the first evidence of a transcrip-
tional control of HA levels in response to oxLDL stimuli. Other
studies already suggested the tight link between regulation of
HAS2 and the production of an abnormal atherosclerotic-re-
lated ECM as found in monocyte-to-macrophage differentia-
tion (43) and by atherosclerosis development in an in vivo
model (52). Although this evidence, together with the high level
of HA found in plaques in vivo, suggests that the synthetic
enzymes (HASs) could be targets to inhibit atherosclerosis and
neointimal expansion, Nagy et al. (3) demonstrated that inhibi-
tion of HA synthesis with 4-methylumbelliferone in proathero-
sclerotic (apoE knock-out) mice accelerated atherosclerosis
because of the glycocalyx damage. A potential pharmacological
treatment based on HA synthesis regulation should therefore
be pinpointed on the HAS expression pathway rather than on
enzymes/substrates control.
Previous studies highlighted the link between HA synthesis
and cholesterol metabolism in AoSMC and in cancer cells (37,
53). In both studies, cholesterol depletion from plasma mem-
brane by methyl--cyclodextrin was associated with decreased
HA accumulation, suggesting a diminished stability of HASs in
membrane microdomains. Our results suggest that membrane
cholesterol content itself, and therefore stabilization of the
enzymes in raft domains, may not be the only reason for HA
modulation. In fact, in our cell model, the membrane loading
with CD-cholesterol complex actually resulted in overexpres-
sion of the enzymeHAS3, which does not seem to be responsi-
ble for theHA augmented release in themedium.Nevertheless,
we cannot exclude that HAS3 is stabilized on the membrane
and might play a different role, for example synthesizing the
pericellular HA used for cellular adhesion and/or migration. It
remains to be elucidatedwhetherHAS2 andHAS3 activation by
oxLDL may be direct (i.e. induction of specific regulator ele-
ments on the proximal promoter of HAS genes) or indirect,
with the activation of other pathways that, in turn, lead to gene
expression. The main cholesterol sensor/regulator in cells are
the ER-bound SREBP complex and the LXR/RXR nuclear
receptor. The SREBP activation as a transcription factor is usu-
ally due to a low level of free cellular cholesterol (46).
It is known that oxLDL can induce ER stress in vascular cells
(54) and that excessive cholesterol uptakemay induce ER stress
FIGURE 5. OxLDL treatment induces ER stress in AoSMC. A and B, quantification of transcripts coding for CHOP (A) and GRP78 (B), ER stress markers, with
respect to control (CNT) in AoSMC treated for 24 h with 20 g of nLDL or oxLDL in the absence () or presence () of 10 g/ml LOX-1 antibody. Values are
mean S.E. of triplicates of two independent experiments, ***, p 0.001. C, quantitative RT-PCR analysis of HAS2 and HAS3 expression of CD-cholesterol and
(22)(R)-hydrocholesterol treatment in AoSMC, each reportedwith respect to its control AoSMC (CNTCD and CNT, respectively). Values aremean S.E. of two
independent experiments, *, p	 0.05, **, p	 0.01, ***, p	 0.001.
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in macrophages (55). Moreover, oxLDL promote in AoSMC an
ECM enriched in versican and most likely HA (which can
account for increased monocyte binding in vitro (12)). Never-
theless, the existence of clear evidence that links oxLDL effects
on ER stress and on ECM modification is still lacking. LDL-
cholesterol (both nLDL and oxLDL)was reported to be released
as unesterified cholesterol in the endosomes that can be driven
either to the plasma membrane or to a lesser extent to the ER
(48, 49). Cholesterol loading in the ERmembrane can establish
a stress condition that may induce the activation of SREBPs
(22). Our results are consistent with this fascinating hypothesis.
In fact, oxLDL treatment of AoSMC was associated with ER
stress induction as demonstrated by CHOP and GRP78
increased mRNA levels and with enhanced HA secretion (50).
In addition, the CF-oxLDL had no effect on HA accumulation.
Concerning ER stress activation of SREBPs, the HAS2 pro-
moter has been proposed to have potential SREBP-2 binding sites,
which can activate up-regulation of HA synthases (37). However,
no clear evidence in support of such a hypothesis has been pre-
sented so far, and recent analysis of SREBPChIP-seq in thehuman
HAS2 locus did not highlight specific peaks within the gene pro-
moter (56). Other pathways involved in regulation of cholesterol
homeostasismaybe responsible forHAS2 activation, onepossibil-
ity being the oxysterol receptor LXR (57). In fact, oxLDL are
reported to include several oxidized species, in particular oxyste-
rols (18). Such speciesmayeitherdirectly activate anLXRpathway
due to specific LXRresponse elementspresent onHAS2promoter
(data not shown) or cause an oxidative stress, whichmay result in
increased deposition of HA because secretion of HA has been
described as amechanism of cell rescue in response to stress (50).
Upon the addition of 22,oxysterols, the strongest of the endoge-
nous LXR agonists, both HAS2 an HAS3 were highly expressed,
reproducing the effect of the oxLDL. In our model, the cell meta-
bolic condition (e.g. the abundance of UDP-sugars), the post-
translational processing of the HASs (e.g. phosphorylation or
O-GlcNAcylation), andRNAtransductioncontrol (microRNA)or
enzymematuration through cell membrane (6) are possible regu-
latory points in which the nonsterol moiety of the LDL has a crit-
ical role in HA final production.
Inconclusion,oxLDLinducesecretionofanHA-enrichedECM
by AoSMC with severe pro-inflammatory properties (e.g.
enhanced migration capacity and adhesiveness). The molecular
events at the basis of this behavior are triggered by a higher
entrance of LDL particles that have been modified by oxidation.
Further events, such as ER stress and activation of the LXR/RXR
nuclear receptor, contribute to expression of HA synthases 2
and 3.
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